Literature DB >> 8959456

Neuropathophysiology of movement disorders in cerebral palsy.

F M Filloux1.   

Abstract

Recent developments in understanding the pathophysiology of disordered motor control in cerebral palsy are reviewed. In spastic cerebral palsy, evidence for abnormal segmental as well as supraspinal control of motor neuron output exists. Impaired Ia inhibition of antagonist muscles has been suggested but recently contested. Evidence also supports the role of decreased presynaptic inhibition of Ia afferents and decreased nonreciprocal Ib inhibition. Furthermore, early cerebral injury results in reorganization of supraspinal (corticospinal) inputs to motor neuron pools. In extrapyramidal cerebral palsy, injury of basal ganglia or thalamus has been demonstrated. A scheme for understanding the neurochemical circuitry of the extrapyramidal system is discussed. Animal models and certain specific human diseases provide examples of how this circuitry may be disturbed, thereby resulting in an imbalance between the direct and indirect striatal output systems and in impaired motor control. Future studies employing postmortem neurochemical analysis, functional magnetic resonance imaging, and positron emission tomographic scanning may foster progress in this area.

Entities:  

Mesh:

Year:  1996        PMID: 8959456     DOI: 10.1177/0883073896011001S02

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  3 in total

1.  Influence of enhanced visual feedback on postural control and spinal reflex modulation during stance.

Authors:  Wolfgang Taube; Christian Leukel; Albert Gollhofer
Journal:  Exp Brain Res       Date:  2008-04-18       Impact factor: 1.972

Review 2.  Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis.

Authors:  R T Schapiro
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

3.  Trunk recruitment during spoon use in tetraparetic cerebral palsy.

Authors:  Dominique van Roon; Bert Steenbergen; Ruud G J Meulenbroek
Journal:  Exp Brain Res       Date:  2003-12-20       Impact factor: 1.972

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.